AFMD | Affimed N.V.

Index- P/E- EPS (ttm)-0.73 Insider Own4.71% Shs Outstand149.34M Perf Week0.49%
Market Cap127.46M Forward P/E- EPS next Y-0.66 Insider Trans0.00% Shs Float140.95M Perf Month1.21%
Income-109.00M PEG- EPS next Q-0.19 Inst Own66.20% Short Float / Ratio3.84% / 7.15 Perf Quarter-2.67%
Sales40.70M P/S3.13 EPS this Y-25.50% Inst Trans-3.34% Short Interest5.41M Perf Half Y-58.99%
Book/sh0.90 P/B0.98 EPS next Y13.40% ROA-46.80% Target Price6.44 Perf Year-71.96%
Cash/sh1.15 P/C0.76 EPS next 5Y- ROE-62.20% 52W Range0.55 - 3.40 Perf YTD-29.22%
Dividend- P/FCF- EPS past 5Y2.60% ROI-51.50% 52W High-74.19% Beta2.51
Dividend %- Quick Ratio5.20 Sales past 5Y83.10% Gross Margin- 52W Low59.52% ATR0.08
Employees219 Current Ratio5.20 Sales Q/Q-43.80% Oper. Margin- RSI (14)48.51 Volatility10.88% 9.58%
OptionableYes Debt/Eq0.13 EPS Q/Q-58.60% Profit Margin- Rel Volume0.50 Prev Close0.85
ShortableYes LT Debt/Eq0.08 EarningsMay 23 BMO Payout- Avg Volume756.46K Price0.88
Recom1.90 SMA20-3.69% SMA505.42% SMA200-39.94% Volume380,890 Change2.82%
Date Action Analyst Rating Change Price Target Change
Dec-12-22Initiated H.C. Wainwright Buy $6
Oct-10-22Downgrade Stifel Buy → Hold $9 → $2
Aug-18-22Resumed Wells Fargo Overweight
Mar-31-22Initiated Piper Sandler Overweight $7
Feb-23-22Initiated Cantor Fitzgerald Overweight $12
Oct-21-21Initiated Truist Buy $10
Sep-30-21Initiated Stifel Buy $12
Mar-31-21Initiated Credit Suisse Outperform $15
Mar-28-19Initiated SVB Leerink Outperform
Aug-28-18Upgrade Jefferies Hold → Buy
Jun-22-15Reiterated Jefferies Buy $12 → $16
Jun-03-23 09:00AM
May-30-23 06:30AM
May-25-23 05:00PM
May-23-23 07:45AM
06:30AM Loading…
May-22-23 06:30AM
May-16-23 06:30AM
May-11-23 10:05AM
May-05-23 06:14AM
Apr-26-23 10:00AM
Apr-17-23 04:05PM
Apr-16-23 03:00PM
Apr-06-23 04:05PM
08:19AM Loading…
Mar-30-23 08:19AM
Mar-29-23 06:30AM
Mar-27-23 06:21AM
Mar-23-23 07:45AM
Mar-16-23 06:30AM
Mar-14-23 04:30PM
Mar-09-23 05:00AM
Feb-22-23 06:30AM
Feb-21-23 05:00AM
Feb-08-23 06:30AM
Jan-09-23 06:30AM
Dec-28-22 06:41AM
Dec-22-22 06:30AM
Dec-16-22 09:35AM
01:01PM Loading…
Dec-12-22 01:01PM
Dec-10-22 03:00PM
Dec-01-22 04:05PM
Nov-17-22 04:01PM
Nov-15-22 07:45AM
Nov-07-22 08:05AM
Nov-04-22 06:30AM
Nov-03-22 09:15AM
Nov-02-22 10:01AM
Nov-01-22 06:30AM
Oct-31-22 07:20PM
Oct-21-22 08:18AM
Oct-10-22 06:42PM
Oct-05-22 08:05AM
Sep-12-22 06:24AM
Sep-04-22 06:05PM
Sep-01-22 06:30AM
Aug-24-22 07:58AM
Aug-20-22 08:48AM
Aug-11-22 08:30AM
Aug-04-22 06:30AM
Jul-13-22 09:02AM
Jun-30-22 04:00PM
Jun-10-22 10:31AM
Jun-01-22 07:55AM
May-26-22 05:05PM
May-25-22 03:00PM
May-24-22 06:30AM
May-16-22 08:00AM
May-14-22 08:06AM
May-12-22 10:31AM
May-06-22 04:02PM
Apr-27-22 05:21PM
Apr-18-22 11:28AM
Apr-12-22 10:02PM
Apr-11-22 03:59PM
Apr-10-22 12:05PM
Apr-08-22 04:19PM
Apr-04-22 03:39PM
Mar-31-22 06:30AM
Mar-24-22 06:30AM
Mar-08-22 04:35PM
Feb-09-22 04:05PM
Feb-08-22 06:30AM
Feb-04-22 09:00AM
Jan-06-22 06:30AM
Jan-05-22 06:30AM
Dec-13-21 09:05AM
Dec-11-21 11:59AM
Dec-09-21 10:38AM
Dec-08-21 06:30AM
Dec-07-21 10:00AM
Dec-05-21 06:04AM
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.